Obese patients have vascular dysfunction related to impaired nitric oxide (NO)-dependent vasodilation and enhanced endothelin (ET)-1 activity. Obestatin is a gastrointestinal peptide with favorable metabolic actions linked to obesity and type 2 diabetes; it has also been shown to exert cardiovascular benefits in experimental models by producing vascular relaxation via specific activation of endothelium-dependent NO signaling. In the present study we tested the hypothesis that obestatin might also have advantageous impacts on the NO pathway and the ET-1 system in patients with central obesity.
Schinzari, F., Tesauro, M., Paoluzzi, A., Mores, N., Rovella, V., DI DANIELE, N., et al. (2015). Obestatin induces nitric oxide-dependent vasodilation and inhibits endothelin-1 activity in human obesity. JOURNAL OF HYPERTENSION, 33(Suppl. 1), E82-E82 [10.1097/01.hjh.0000467572.56702.55].
Obestatin induces nitric oxide-dependent vasodilation and inhibits endothelin-1 activity in human obesity
TESAURO, MANFREDI;ROVELLA, VALENTINA;DI DANIELE, NICOLA;
2015-06-01
Abstract
Obese patients have vascular dysfunction related to impaired nitric oxide (NO)-dependent vasodilation and enhanced endothelin (ET)-1 activity. Obestatin is a gastrointestinal peptide with favorable metabolic actions linked to obesity and type 2 diabetes; it has also been shown to exert cardiovascular benefits in experimental models by producing vascular relaxation via specific activation of endothelium-dependent NO signaling. In the present study we tested the hypothesis that obestatin might also have advantageous impacts on the NO pathway and the ET-1 system in patients with central obesity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
